Form 4: Bioxytran Director Anders Utter Executes Stock Conversion and Transactions

Anders Utter, a director at Bioxytran, Inc., executed a 5:1 exchange of common stock for convertible preferred stock and reported transactions involving the company's securities.

Summary

• On August 16, 2024, Anders Utter acquired 123,967 shares of common stock at $0.121 per share.
• On August 19, 2024, Utter disposed of 1,079,189 shares of common stock at $0.165 per share.
• Also on August 19, 2024, Utter acquired 215,838 shares of preferred stock at $0.825 per share.
• These transactions involved a 5:1 exchange of common stock into convertible preferred stock, with a conversion ratio of 1:5 shares into common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It's important for investors to monitor such filings to understand the actions of key personnel.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of confidence in the company's future prospects.

Key Dates

Keywords

Bioxytran, Anders Utter, Form 4, Stock Conversion, Preferred Stock, Common Stock, BIXT, Director, Securities